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MedTech and 
Diagnostics
EV ARRAY
- High-throughput Multiplexed Phenotyping 
of Extracellular Vesicles (EVs)
Value proposition / USP 
EV Array is an unique biomarker platform that can
exploit the intercellular trafficking in various biofluids
to provide a non-invasive method for diagnostics and
prognostics.
Business Opportunity / Objective / Commercial Perspectives
The apparent role of EVs in a vast number of biological processes, forms the basis of extending EV analysis beyond basic research and into clinical and therapeutic
context. The applications of this type of analysis include the areas of diagnostics and prognostics, as well as drug therapy, regenerative medicine, and vaccines. The
analysis of EVs could be incorporated as a screening tool and applied to confirm a diagnosis. Furthermore, the EV Array analysis has the potential to become an
element in treatment surveillance and companion diagnostics.
Technology Description / Technology Summary
The EV Array is based on the technology of protein microarray and allows for the detection and phenotyping of EVs from unpurified starting material in a high-throughput manner. The technology was developed to perform
multiplexed phenotyping of EVs in an open platform. The EV Array has been optimized for plasma, but can analyze urine, saliva, ascites, bone marrow, and cerebrospinal-, synovial- and bronchoalveolar fluids as well.
Development Phase / Current state
The current stage of the EV Array technology is a fully developed analysis
optimized for a small-to-medium laboratory research scale. Several studies has
demonstrated the EV Array efficiency in detecting cancers, lung-related diseases
(pneumonia, COPD), venous thrombosis, multiple sclerosis and malaria.
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All living cells produce extracellular vesicles (EVs),
which are nano-sized compartments. They are
considered as a pivotal part of the intercellular
environment and act as important players in cell-
to-cell communication. The fact, that EVs are
involved in the development and progression of
several diseases, has formed the basis for the use
of EV analyses in a clinical setting and envisions a
great potential for using EVs as disease-related
biomarkers.
EVs are a heterogeneous population of membrane
-enclosed vesicles that can be divided into a
number of subpopulations based on specific
characteristics such as size, biogenesis, cellular
origin, protein composition, and biological
function. The two major subtypes of EVs are
exosomes and microvesicles.
Extracellular Vesicles (EVs)
The diagnostic power of the EVs to identify lung cancer
patients can be visualized by the receiver operating
characteristics (ROC), which shows the models’ sensitivity,
specificity and accuracy. The data presented was obtained by
analyzing EVs from 10 µL of plasma from 109 lung cancer
patients (non-small cell lung cancer, NSCLC) together with
110 lung diseased patients (non-cancerous). A panel of 37
different EV markers were analyzed simultaneously and a
multivariate data analysis was performed. Using the results
from 30 of the variables it was possible to distinguish lung
cancer patients from other lung diseased patients with a
specificity of 79% and a sensitivity of 73% with an accuracy of
76%.
Diagnostic and Prognostic Tool for Lung Cancer (NSCLC)
Prognostic biomarkers are needed to improve patient selection for
optimal treatment. We have evaluated EVs as a prognostic
biomarker in NSCLC analyzing EVs in plasma from 276 NSCLC
patients using the EV Array. Several markers were found to correlate
to the overall survival (OS) of the patients. As shown on the survival
curve, patients with CD171 positive EVs (blue curve) had a better
overall survival with a 9.5 months longer median survival compared
to patients without CD171 on their EVs (yellow curve).
Other markers, as e.g. EGFR and NY-ESO-1, were found to influence
the overall survival in a concentration-dependent manner. Patients
with high levels of EVs positive for any one of these markers were
found have a significantly lower mortality rate, with up to 4.6-times
for EGFR. This indicates that high levels of specific EVs are
protecting the patients against the cancer.
A) Barcoded microarray glass slides (7.5 x 2.5cm) printed in a 21-well setup.
B) Printed slides are placed in multiwell-cassettes for either one glass slide (up
to 21 samples) or four glass slides (up to 84 samples).
C) The procedure is validated by a quality control of the printed spots, which
includes positive and negative controls.
D) Scanning after capture and detection of EVs can be performed on a normal
laboratory fluorescence scanner or on a specialized microarray scanner for
maximum sensitivity.
EV Array in Practice
More Information
Detailed information about the 
technology can be found at: 
WWW.EVARRAY.DK
Step 1: The EV Array is
composed of different capture
antibodies printed on a micro-
array slide.
Step 2: 10-100 µL plasma or
other body fluids (urine, saliva,
BALF, etc.) are applied in a 96-
well setup and incubated 2
hours to overnight.
Step 3: The EVs are detected
with a cocktail of biotinylated
antibodies.
Step 4/5: The presence and
thereby phenotype of EVs is
visualized after incubation with
Cy5-labeled Streptavidin using a
fluorescence scanner.
Principle of the Extracellular Vesicle Array (EV Array)
